<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006032</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-12220</org_study_id>
    <secondary_id>MCC-12220</secondary_id>
    <secondary_id>MCC-IRB-5699</secondary_id>
    <secondary_id>NCI-G00-1809</secondary_id>
    <nct_id>NCT00006032</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer</brief_title>
  <official_title>A Phase II Study of Intensive-Dose Topotecan, Ifosfamide/Mesna and Etoposide (TIME) Followed by Autologous Stem Cell Rescue in Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation&#xD;
      may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by&#xD;
      autologous peripheral stem cell transplantation in treating women who have metastatic breast&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Evaluate the efficacy and toxicity of high dose topotecan with ifosfamide and&#xD;
      etoposide followed by autologous peripheral blood stem cell rescue in women with metastatic&#xD;
      breast cancer. II. Evaluate the response rates, progression free survival, engraftment, and&#xD;
      nonrelapse related mortality in women treated with this regimen. III. Evaluate the&#xD;
      pharmacokinetic profile of high dose topotecan with respect to the efficacy and toxicity of&#xD;
      ifosfamide and etoposide in these women.&#xD;
&#xD;
      OUTLINE: Peripheral blood stem cells (PBSC) are harvested from the patient and stored.&#xD;
      Patients receive ifosfamide IV over 2 hours and topotecan IV over 30 minutes on days -8 to&#xD;
      -6, and etoposide IV daily over 24 hours on days -5 to -3. Autologous PBSC are reinfused on&#xD;
      day 0. Patients are followed at 1, 3, 6, and 12 months, and then every 6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study over 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual&#xD;
  </why_stopped>
  <start_date>March 2000</start_date>
  <completion_date type="Actual">April 2001</completion_date>
  <primary_completion_date type="Actual">April 2001</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed metastatic breast cancer that has&#xD;
        demonstrated at least partial response to any salvage regimen Partial response defined as&#xD;
        at least 50% reduction in measurable or evaluable disease for at least 4 weeks, no disease&#xD;
        progression, no new lesions, or bone lesions that remain static for at least 8 weeks with&#xD;
        an improvement in pain symptoms No more than 3 organs involved with metastatic disease No&#xD;
        prior or active CNS involvement Hormone receptor status: Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 to 64 Sex: Female Menopausal status: Not specified&#xD;
        Performance status: ECOG 0-1 Life expectancy: Not specified Hematopoietic: Not specified&#xD;
        Hepatic: Bilirubin no greater than 2.0 mg/dL SGOT or SGPT no greater than 2.5 times upper&#xD;
        limit of normal No history of severe hepatic dysfunction Renal: Creatinine no greater than&#xD;
        2.0 mg/dL OR Creatinine clearance at least 60 mL/min Cardiovascular: No severe cardiac&#xD;
        dysfunction Ejection fraction at least 50% by MUGA No major heart disease Controlled&#xD;
        hypertension allowed Pulmonary: DLCO at least 50% of normal OR No symptomatic obstructive&#xD;
        or restrictive disease Other: Not pregnant or nursing Negative pregnancy test Fertile&#xD;
        patients must use effective barrier contraception No uncontrolled insulin dependent&#xD;
        diabetes mellitus No uncompensated major thyroid or adrenal dysfunction No significant skin&#xD;
        breakdown from tumor or other disease No other prior malignancy in past 5 years except&#xD;
        nonmelanoma skin cancer or carcinoma in situ of the cervix No active infections HIV&#xD;
        negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease&#xD;
        Characteristics No more than 2 prior salvage regimens for metastatic disease No prior&#xD;
        topotecan Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not&#xD;
        specified Other: No concurrent nitroglycerin preparations for angina No concurrent&#xD;
        antiarrhythmics for major ventricular arrhythmias&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen K. Fields, MD</last_name>
    <role>Study Chair</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>April 1, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2004</study_first_posted>
  <last_update_submitted>December 10, 2012</last_update_submitted>
  <last_update_submitted_qc>December 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

